Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors for 3,225,000 shares of common stock.
The offering price is set at $1.20 per share, with expected gross proceeds of approximately $3.9 million.
The offering is scheduled to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share, totaling $3.9 million in gross proceeds.
Placement Agent
Maxim Group LLC is serving as the sole placement agent for the offering.
Registration Statement
The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-289198) filed with the SEC on August 1, 2025.
- The offering provides Scienture Holdings with additional funding to support its pharmaceutical operations and product development.
- This direct offering enhances the Company's financial position and allows it to pursue its strategic objectives with increased capital.
The successful completion of this registered direct offering signifies a milestone for Scienture Holdings in securing additional investment for its pharmaceutical ventures.